Market Overview

Guggenheim Securities Initiates ANI Pharma With Buy


Guggenheim Securities initiated coverage on ANI Pharma (NASDAQ: ANIP) with a Buy rating.

The target price for ANI Pharma is set to $65.

ANI Pharma shares have gained 259.71% over the past 52 weeks, while the S&P 500 index has surged 12.08% in the same period.

ANI Pharma shares rose 4.49% to close at $54.28 on Friday.

Latest Ratings for ANIP

Sep 2019Initiates Coverage OnBuy
May 2019DowngradesStrong BuyOutperform
Nov 2018MaintainsBuyBuy

View More Analyst Ratings for ANIP
View the Latest Analyst Ratings

Posted-In: Guggenheim SecuritiesInitiation Analyst Ratings


Related Articles (ANIP)

View Comments and Join the Discussion!

Latest Ratings

HSKACanaccord GenuityMaintains75.0
AVGOMorgan StanleyMaintains265.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Why Deutsche Bank Downgraded Ford

Coffee, Sugar Futures Trading Higher